title: Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
abstract: OBJECTIVE
  Alterations in the p53 tumor suppressor gene located on human chromosome 17p13.1 are currently the most common genetic abnormalities associated with many different types of human malignancies. Recently serum p53 antibodies (p53-Abs) have been detected in the serum of patients with various cancers. To evaluate the clinical usefulness of serum p53-Abs we compared p53-Abs with prostate specific antigen (PSA) parameters in patients with benign prostatic disease (BPD) and prostate cancer.
  
  
  METHODS
  Serum samples were obtained from 50 patients with BPD and 103 with histologically diagnosed prostate cancer, including T1c/2N0M0 in 50, T3N0M0 in 29 and TxNxM1 in 24. The serum p53-Abs titer was assessed by enzyme-linked immunoabsorbent assay using a MESCUP Kit II (Medical and Biological Laboratories Co., Ltd., Nagoya, Japan) antip53 test. Free and total PSA was measured using an Architect (Dinabott, Chicago, Illinois) PSA kit. The clinical values of p53-Abs were compared with total PSA, PSA density (PSAD), PSA density of the transition zone (PSATZD) and the free-to-total PSA ratio using ROC curves.
  
  
  RESULTS
  All patients with prostate cancer had significantly higher total PSA, PSAD, PSATZD and p53-Abs than patients with BPD. While total PSA, PSAD, PSATZD and free-to-total PSA ratios were associated with stage progression, serum p53-Abs were not related to clinical stage. The Gleason sum 5 or less group had a higher level of p53-Abs than higher Gleason sum groups. Patients with T1c cancer had significantly higher p53-Abs than those with BPD. According to ROC curve analysis to distinguish prostate cancer from BPD the p53-Abs titer had the greatest AUC in the overall patient population and in patients without digital rectal examination findings.
  
  
  CONCLUSIONS
  These results suggest that p53-Abs might be helpful in the clinical decision to perform prostate biopsy. In the current study the serum p53-Abs titer had the most useful validity in discriminating between prostate cancer and BPD in the overall patient population and in patients with normal digital rectal examination.
authors.affiliation: Department of Urology, Graduate School of Medicine, Chiba University, Japan. hirosuzu@ho.chiba-u.ac.jp
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Suzuki
authors.forename: Koichiro
authors.initials: K
authors.lastname: Akakura
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Igarashi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ueda
authors.forename: Haruo
authors.initials: H
authors.lastname: Ito
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Watanabe
authors.forename: Fumio
authors.initials: F
authors.lastname: Nomura
authors.forename: Takenori
authors.initials: T
authors.lastname: Ochiai
authors.forename: Hidekii
authors.initials: H
authors.lastname: Shimada
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000912:Antibodies, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis*; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53; D017430:Prostate-Specific Antigen